Translating the role of PARP inhibitors in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is a heterogeneous and aggressive subtype of breast cancer that lacks expression of estrogen receptor (ER), progesterone receptor (PR), and HER2. Patients with TNBC have a poorer overall survival and tend to progress within three years of diagnosis [1]. The therapeutic management of TNBC is a significant challenge, since patients cannot benefit from antihormonal or HER2-directed therapy, and are commonly offered several types of cytotoxic chemotherapy